CY1123732T1 - Σταθερα πολυπεπτιδια τα οποια δεσμευονται σε c5 ανθρωπινου συμπληρωματος - Google Patents

Σταθερα πολυπεπτιδια τα οποια δεσμευονται σε c5 ανθρωπινου συμπληρωματος

Info

Publication number
CY1123732T1
CY1123732T1 CY20201101229T CY201101229T CY1123732T1 CY 1123732 T1 CY1123732 T1 CY 1123732T1 CY 20201101229 T CY20201101229 T CY 20201101229T CY 201101229 T CY201101229 T CY 201101229T CY 1123732 T1 CY1123732 T1 CY 1123732T1
Authority
CY
Cyprus
Prior art keywords
bind
human complement
stable polypeptides
polypeptides
stable
Prior art date
Application number
CY20201101229T
Other languages
Greek (el)
English (en)
Inventor
Joakim Nilsson
Erik Nordling
Patrik STRÖMBERG
Original Assignee
Ipc Research, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipc Research, Llc filed Critical Ipc Research, Llc
Publication of CY1123732T1 publication Critical patent/CY1123732T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
CY20201101229T 2013-08-28 2020-12-30 Σταθερα πολυπεπτιδια τα οποια δεσμευονται σε c5 ανθρωπινου συμπληρωματος CY1123732T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1350986 2013-08-28
PCT/EP2014/068282 WO2015028558A1 (en) 2013-08-28 2014-08-28 Stable polypeptides binding to human complement c5

Publications (1)

Publication Number Publication Date
CY1123732T1 true CY1123732T1 (el) 2021-10-29

Family

ID=51539238

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201101229T CY1123732T1 (el) 2013-08-28 2020-12-30 Σταθερα πολυπεπτιδια τα οποια δεσμευονται σε c5 ανθρωπινου συμπληρωματος

Country Status (29)

Country Link
US (1) US9994626B2 (https=)
EP (2) EP3038633B1 (https=)
JP (2) JP6767865B2 (https=)
KR (1) KR102446636B1 (https=)
CN (1) CN105658228B (https=)
AU (1) AU2014314222B2 (https=)
BR (1) BR112016003142A2 (https=)
CA (1) CA2926976C (https=)
CY (1) CY1123732T1 (https=)
DK (1) DK3038633T3 (https=)
ES (1) ES2842105T3 (https=)
HR (1) HRP20210013T1 (https=)
HU (1) HUE052613T2 (https=)
IL (1) IL244218A (https=)
LT (1) LT3038633T (https=)
MX (1) MX382140B (https=)
MY (1) MY173804A (https=)
NZ (1) NZ718153A (https=)
PH (1) PH12016500371B1 (https=)
PL (1) PL3038633T3 (https=)
PT (1) PT3038633T (https=)
RS (1) RS61347B1 (https=)
RU (2) RU2020128977A (https=)
SA (1) SA516370622B1 (https=)
SG (1) SG11201602679VA (https=)
SI (1) SI3038633T1 (https=)
SM (1) SMT202100006T1 (https=)
UA (1) UA117933C2 (https=)
WO (1) WO2015028558A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013126006A1 (en) * 2012-02-20 2013-08-29 Swedish Orphan Biovitrum Ab (Publ) Polypeptides binding to human complement c5
MX367423B (es) 2013-08-28 2019-08-21 Affibody Ab Polipeptidos de union a c5.
CN105658228B (zh) * 2013-08-28 2020-02-07 瑞典孤儿比奥维特鲁姆有限公司 结合人类补体c5的稳定多肽
UY37651A (es) * 2017-03-31 2018-10-31 Swedish Orphan Biovitrum Ab Publ Polipéptido de unión al il-1r-i
BR112019028269A2 (pt) 2017-07-11 2020-07-14 Alexion Pharmaceuticals, Inc. polipeptídeos que se ligam ao componente c5 do complemento ou à albumina sérica e suas proteínas de fusão
JP2024506070A (ja) * 2021-02-15 2024-02-08 アフィボディ アクティエボラーグ 新規her2結合ポリペプチド
CA3237246A1 (en) * 2021-11-01 2023-05-04 Ipc Research, Llc Administration of c5-binding proteins
WO2024227886A1 (en) 2023-05-02 2024-11-07 Mebrahtu Aman Bispecific binding molecule

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
AU2001296594A1 (en) 2000-10-10 2002-04-22 Tanox, Inc. Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection
AT410798B (de) * 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
BRPI0211953B8 (pt) * 2001-08-17 2021-05-25 Genentech Inc anticorpo monoclonal ou fragmento de ligação a antígeno que se liga a c5 e c5a sem a prevenção da formação de c5b, linhagem celular, composição farmacêutica, bem como método in vitro para inibir a atividade de c5a e método de diagnóstico in vitro
ITMI20021527A1 (it) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
WO2005023866A2 (en) 2003-09-10 2005-03-17 Baxter International Inc. Peptides that inhibit complement activation
SE0400274D0 (sv) * 2004-02-09 2004-02-09 Affibody Ab New polypeptide
GB0518443D0 (en) * 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
KR101584468B1 (ko) * 2006-03-08 2016-01-13 아케믹스 엘엘씨 안질환의 치료에 유용한 보체 결합 앱타머 및 항-c5 제제
PL3167888T3 (pl) 2006-03-15 2024-08-26 Alexion Pharmaceuticals, Inc. Leczenie pacjentów z napadową nocną hemoglobinurią za pomocą inhibitora dopełniacza
CA2694139C (en) 2007-07-31 2018-06-05 Affibody Ab Albumin binding polypeptide compositions
DK2231860T3 (da) * 2007-12-19 2011-12-05 Affibody Ab Polypeptid afledt protein A og i stand til at binde PDGF
US9187535B2 (en) 2007-12-19 2015-11-17 Affibody Ab Polypeptide derived from protein A and able to bind PDGF
EP2072525A1 (en) 2007-12-21 2009-06-24 Affibody AB New polypeptides having affinity for HER2
PY09026846A (es) 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
EP2327725A1 (en) 2009-11-26 2011-06-01 InflaRx GmbH Anti-C5a binding moieties with high blocking activity
MX2013000314A (es) 2010-07-09 2013-01-29 Affibody Ab Polipeptidos.
WO2013126006A1 (en) 2012-02-20 2013-08-29 Swedish Orphan Biovitrum Ab (Publ) Polypeptides binding to human complement c5
JP5980104B2 (ja) 2012-11-22 2016-08-31 三菱電機株式会社 液晶表示装置の製造方法および液晶表示装置の製造システム
EP2935335B1 (en) 2012-12-19 2020-10-28 Affibody AB New polypeptides
MX367423B (es) 2013-08-28 2019-08-21 Affibody Ab Polipeptidos de union a c5.
CN105658228B (zh) * 2013-08-28 2020-02-07 瑞典孤儿比奥维特鲁姆有限公司 结合人类补体c5的稳定多肽

Also Published As

Publication number Publication date
HRP20210013T1 (hr) 2021-04-02
WO2015028558A1 (en) 2015-03-05
IL244218A (en) 2017-11-30
EP3811961A1 (en) 2021-04-28
PL3038633T3 (pl) 2021-07-19
RS61347B1 (sr) 2021-02-26
UA117933C2 (uk) 2018-10-25
KR20160048121A (ko) 2016-05-03
IL244218A0 (en) 2016-04-21
US9994626B2 (en) 2018-06-12
PH12016500371A1 (en) 2016-05-02
MY173804A (en) 2020-02-24
NZ718153A (en) 2022-05-27
PH12016500371B1 (en) 2016-05-02
KR102446636B1 (ko) 2022-09-23
MX2016002397A (es) 2016-09-08
JP2016529270A (ja) 2016-09-23
SG11201602679VA (en) 2016-05-30
CN105658228A (zh) 2016-06-08
EP3811961B1 (en) 2025-08-20
AU2014314222A1 (en) 2016-04-21
RU2733897C2 (ru) 2020-10-09
CA2926976C (en) 2023-11-28
CA2926976A1 (en) 2015-03-05
HK1225656A1 (en) 2017-09-15
SI3038633T1 (sl) 2021-05-31
AU2014314222B2 (en) 2018-05-24
BR112016003142A2 (pt) 2017-10-17
US20160311870A1 (en) 2016-10-27
SA516370622B1 (ar) 2018-12-23
EP3038633A1 (en) 2016-07-06
HUE052613T2 (hu) 2021-05-28
RU2020128977A (ru) 2021-11-30
DK3038633T3 (da) 2021-01-11
RU2016111115A (ru) 2017-10-03
BR122023020080A2 (pt) 2023-12-26
CN105658228B (zh) 2020-02-07
JP6767865B2 (ja) 2020-10-14
MX382140B (es) 2025-03-13
EP3038633B1 (en) 2020-10-14
LT3038633T (lt) 2021-03-25
RU2016111115A3 (https=) 2018-04-25
PT3038633T (pt) 2021-01-14
JP2020172505A (ja) 2020-10-22
ES2842105T3 (es) 2021-07-12
SMT202100006T1 (it) 2021-03-15

Similar Documents

Publication Publication Date Title
CY1123732T1 (el) Σταθερα πολυπεπτιδια τα οποια δεσμευονται σε c5 ανθρωπινου συμπληρωματος
CY1125440T1 (el) Αντι-τιμ-3 αντισωματα και συνθεσεις
CY1121347T1 (el) Πρωτεϊνη συντηξης
CY1124563T1 (el) Βελτιωμενα antισωmata δεσμευσης πρωτοϊνιδιων α- βητα
CY1123163T1 (el) Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων
CY1121893T1 (el) Μορια αντισωματος κατα της τιμ-3 και χρησεις αυτων
MX2020009568A (es) Anticuerpos que se unen a cd39 y sus usos.
CO2018009995A2 (es) Proteínas de unión y métodos de uso de las mismas
EA202191806A1 (ru) Антитело против человеческого il-4ra и его применение
CY1119213T1 (el) Πρωτεϊνη p75ntr συνδεσης νευροτροφινης για θεραπευτικη χρηση
CY1122060T1 (el) Συνδυαστικη θεραπευτικη χρηση αντισωματων και ενδογλυκοσιδασεων
CY1124682T1 (el) Ανταγωνιστες toy trpv4
CY1119030T1 (el) Χρηση των δεσμων σιγμα στον πονο του καρκινου των οστων
MX2024006565A (es) Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos.
CY1121964T1 (el) Αντισωματα εναντιον toy csf-1r
CU20170169A7 (es) Anticuerpos de factor xi
CY1121736T1 (el) Άλατα aramchol
CY1122214T1 (el) Αντισωματα ειδικα για ton fcrn
BR112018075653A2 (pt) anticorpos anti-b7-h3 e conjugados anticorpo fármaco
CY1123403T1 (el) Τροποποιημενα κυτταρα ξενιστες και χρησεις αυτων
GEP20217326B (en) Constructs having a sirp-alpha domain or variant thereof
BR112016012358A2 (pt) peptídios terapêuticos
CL2012001141A1 (es) Anticuerpo aislado o fragmento de este que se une específicamente a interleuquina-17a (il-17a) humana.
BR112018075644A2 (pt) anticorpos anti-cd98 e conjugados de anticorpo e fármaco
CY1116646T1 (el) Αντικαρκινικη πρωτεϊνη συντηξης